{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:18Z","timestamp":1792931838479,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Low-dose cytarabine treatment reduced mortality in symptomatic TMD patients compared with the historical control. An MRD monitoring\u2013based low-dose cytarabine treatment does not prevent progression from preleukemic TMD to ML-DS.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018018945","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T12:00:30Z","timestamp":1530273630000},"page":"1532-1540","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study"],"prefix":"10.1182","volume":"2","author":[{"given":"Marius","family":"Flasinski","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Scheibke","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Creutzig","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Verwer","sequence":"additional","affiliation":[{"name":"Dutch Childhood Oncology Group, Den Haag, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"de Haas","sequence":"additional","affiliation":[{"name":"Dutch Childhood Oncology Group, Den Haag, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Immunology, Laboratory Medical Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"von Neuhoff","sequence":"additional","affiliation":[{"name":"Department of Pediatric Psychiatry and Psychosomatic Medicine, Landschaftsverband-Rheinland Clinic, University Duisburg\/Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"Dutch Childhood Oncology Group, Den Haag, The Netherlands;"},{"name":"Department of Pediatric Oncology\/Hematology, Erasmus Medical Center\/Sophia Children's Hospital, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"issue":"6","key":"2019111623040540800_B1","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2007-01-069542","article-title":"Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome","volume":"110","author":"Pine","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111623040540800_B2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-2005-836510","article-title":"Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts","volume":"217","author":"Langebrake","year":"2005","journal-title":"Klin Padiatr"},{"issue":"24","key":"2019111623040540800_B3","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2019111623040540800_B4","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children\u2019s Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111623040540800_B5","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111623040540800_B6","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2005-06-2448","article-title":"A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children\u2019s Oncology Group (COG) study POG-9481","volume":"107","author":"Massey","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111623040540800_B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2008.07231.x","article-title":"Risk factors for early death in neonates with Down syndrome and transient leukaemia","volume":"142","author":"Muramatsu","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111623040540800_B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00043426-200201000-00004","article-title":"Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study","volume":"24","author":"Al-Kasim","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"2019111623040540800_B9","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2011-03-342774","article-title":"Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia","volume":"118","author":"Alford","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111623040540800_B10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"11","key":"2019111623040540800_B11","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111623040540800_B12","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"issue":"21","key":"2019111623040540800_B13","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1182\/blood-2012-12-474387","article-title":"Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome","volume":"121","author":"Saida","year":"2013","journal-title":"Blood"},{"issue":"25","key":"2019111623040540800_B14","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"key":"2019111623040540800_B15","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"issue":"3","key":"2019111623040540800_B16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"282","key":"2019111623040540800_B17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2019111623040540800_B18","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"9","key":"2019111623040540800_B19","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood.V100.9.3352","article-title":"Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities","volume":"100","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111623040540800_B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/leu.2013.264","article-title":"Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy","volume":"28","author":"Stankov","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111623040540800_B21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/pbc.26062","article-title":"Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome","volume":"63","author":"Scheer","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2019111623040540800_B22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders [published correction appears in Nat Genet. 2013;45(12):1516]","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"2019111623040540800_B23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1532\/881442\/advances018945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/13\/1532\/881442\/advances018945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T23:04:21Z","timestamp":1573945461000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/13\/1532\/15946\/Lowdose-cytarabine-to-prevent-myeloid-leukemia-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,7,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018018945","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]}}}